USPTO serial 87093891
CRUZ VERDE AMERICA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- RYDLAND, STEPHANIE DIANA
- Law office
- LAW OFFICE 117 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with CRUZ VERDE AMERICA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Thousand Oaks, CA
Thousand Oaks, CA
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Acetaminophen; Antacids; Antibiotic creams; Antibiotic handwash; Antibiotic ointments; Antibiotic preparations; Antibiotic tablets; Antibiotics; Antihistamines; Aspirin; Cough drops; Cough syrups; Cough expectorants; Decongestant capsules; Decongestant nasal sprays; Decongestants; Dietary food supplements; Eye drops; Laxatives; Oral analgesics; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents for epidermis; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparation for skin care; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals, namely, anti-infectives; Sleeping pills/tablets; Suppositories; Topical analgesic creams; Topical analgesics; Vitamin and mineral supplements; Alcohol for pharmaceutical purposes; Aloe vera preparations for pharmaceutical purposes; Analgesic and muscle relaxant pharmaceutical preparations; Anti-cough drops; Antibacterial pharmaceuticals; Balms for pharmaceutical purposes; Bee pollen for use as a dietary food supplement; Dermatological pharmaceutical products; Dietary supplemental drinks in the nature of vitamin and mineral beverages; Digestives for pharmaceutical purposes; Ibuprofen for use as an oral analgesic; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Jalap; Menthol for pharmaceutical purposes; Multipurpose medicated antibiotic cream, analgesic balm and mentholated salve; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 15, 2017 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 15, 2017 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 17, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 17, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 17, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 17, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 12, 2016 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 11, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 9, 2016 | NWAP | NEW APPLICATION ENTERED | — |